SCHEMBL5592585

SCHEMBL5592585

COc1ccc(Cl)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
EPHB4 P54760 3/20 0.47
KDM4E B2RXH2 3/20 0.46
MAPT P10636 4/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
IGF1R P08069 3/20 0.46
POLB P06746 3/20 0.45
TP53 P04637 2/20 0.44
NTRK1 P04629 2/20 0.44
NTRK2 Q16620 2/20 0.44
LMNA P02545 1/20 0.43
ALOX12 P18054 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166253 0.94 EPHB4 (0.42) MEN1KMT2AEPHB4KDM4EMAPT
SCHEMBL5612923 0.92 THRB (0.42) MEN1KMT2AEPHB4KDM4EMAPT
SCHEMBL165575 0.92 EPHB4 (0.46) MEN1KMT2AEPHB4KDM4EMAPT
Hydrochloric Acid SCHEMBL168314 0.91 EPHB4 (0.45) MEN1KMT2AEPHB4KDM4EMAPT
SCHEMBL5959796 0.91 MEN1 (0.50) MEN1KMT2AEPHB4KDM4EMAPT
SCHEMBL5592945 0.90 MAPT (0.50) MEN1KMT2AEPHB4KDM4EMAPT
Ji-101 SCHEMBL5585996 0.90 EPHB4 (0.46) MEN1KMT2AEPHB4KDM4EMAPT
Ji-101 SCHEMBL29375077 0.90 EPHB4 (0.46) MEN1KMT2AEPHB4KDM4EMAPT
SCHEMBL5959896 0.90 MEN1 (0.46) MEN1KMT2AEPHB4KDM4EMAPT
Ji-101 SCHEMBL14993319 0.89 EPHB4 (0.45) MEN1KMT2AEPHB4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL MEN1 3417/4885KMT2A 3501/4885EPHB4 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.